TFX - Teleflex Incorporated

NYSE - NYSE Delayed Price. Currency in USD
262.17
+1.51 (+0.58%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close260.66
Open258.45
Bid0.00 x 100
Ask0.00 x 1100
Day's Range255.76 - 266.34
52 Week Range227.52 - 288.78
Volume254,571
Avg. Volume338,995
Market Cap12.055B
Beta (3Y Monthly)1.28
PE Ratio (TTM)180.31
EPS (TTM)1.45
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & Yield1.36 (0.52%)
Ex-Dividend Date2018-11-14
1y Target Est299.22
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Teleflex Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Teleflex Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire14 days ago

    NeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH). If BPH is left untreated, the condition can worsen over time and cause permanent bladder damage. The Company estimates there are about 2.3 million men age 50 and older in Japan who have been diagnosed with BPH1.

  • Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up
    Zacks17 days ago

    Teleflex (TFX) Q3 Earnings Surpass Estimates, EPS View Up

    Teleflex (TFX) consistently rides high on a robust uptick in revenues, backed by stable segmental growth and solid geographical expansions.

  • Teleflex Inc. (TFX) Q3 2018 Earnings Conference Call Transcript
    Motley Fool18 days ago

    Teleflex Inc. (TFX) Q3 2018 Earnings Conference Call Transcript

    TFX earnings call for the period ending September 30, 2018.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of TFX earnings conference call or presentation 1-Nov-18 12:00pm GMT

    Q3 2018 Teleflex Inc Earnings Call

  • Associated Press18 days ago

    Teleflex: 3Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had net income of $1.21 per share. Earnings, adjusted for amortization costs and restructuring costs, were $2.52 per share. The results topped Wall Street ...

  • Business Wire18 days ago

    Teleflex Announces Quarterly Dividend

    Teleflex Incorporated announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock. The dividend is payable December 14, 2018 to shareholders of record at the close of business on November 15, 2018.

  • Business Wire18 days ago

    Teleflex Reports Third Quarter 2018 Results

    Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis

  • Business Wire19 days ago

    Teleflex to Present at the Credit Suisse 27th Annual Healthcare Conference

    Liam Kelly, President and CEO, Teleflex Incorporated , is scheduled to speak at the Credit Suisse 27th Annual Healthcare Conference at The Phoenician in Scottsdale, AZ, Wednesday, November 14, 2018 at 11:30 a.m.

  • Business Wire21 days ago

    Teleflex Receives 2018 Medical Design Excellence Award (MDEA) for Arrow® AC3 OptimusTM Intra-Aortic Balloon Pump

    Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, is proud to announce the Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the bronze winner in the cardiovascular device category of the 20th annual Medical Design Excellence Awards competition. The AC3 Optimus IABP helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy.

  • Business Wire21 days ago

    NeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the company received the Phoenix 2018 Emerging Growth Company Award at the 25th Annual Phoenix Medical Device and Diagnostic Conference in Laguna Beach, Calif. sponsored by the firm Wilson Sonsini Goodrich & Rosati. The Emerging Growth Company award is presented to an organization that has undergone a strategically significant merger, a highly successful IPO, dramatic growth in sales, or the creation of a major new product or service. Last year, NeoTract was acquired by Teleflex Incorporated in a transaction valued at up to $1.1 billion.

  • Business Wire26 days ago

    NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England

    The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear.

  • Business Wire26 days ago

    NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England

    The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear.

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind Teleflex, Loral Space and Communications, MSCI, Mid-America Apartment Communities, Huntington Ingalls Industries, and Korea Electric Power — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wirelast month

    Teleflex Announces Third Quarter 2018 Earnings Conference Call Information

    Live Webcast is scheduled at 8:00 a.m. on Thursday, November 1, 2018

  • Business Wirelast month

    NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged Prostate

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). The real-world study, which enrolled 100 patients at a single center, evaluated the UroLift System treatment for lower urinary tract symptoms (LUTS) in men with BPH.

  • See what the IHS Markit Score report has to say about Teleflex Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Teleflex Inc.

    To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Teleflex's Latest Essential Medical Buyout to Broaden Suite
    Zackslast month

    Teleflex's Latest Essential Medical Buyout to Broaden Suite

    Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.

  • Business Wirelast month

    Teleflex Acquires Essential Medical

    Teleflex Incorporated (TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE Marked MANTA™ Vascular Closure Device specifically designed for closure of large bore arteriotomies following procedures utilizing devices or sheaths ranging in size from 10F to 18F (with maximum outer diameters up to 25F). “We are very excited to announce this acquisition, which expands our presence in the structural heart and endovascular aneurysm repair markets,” said Liam Kelly, President and Chief Executive Officer of Teleflex.

  • Simply Wall St.2 months ago

    At US$271, Is It Time To Put Teleflex Incorporated (NYSE:TFX) On Your Watch List?

    Today we’re going to take a look at the well-established Teleflex Incorporated (NYSE:TFX). The company’s stock saw a double-digit share price rise of over 10% in the past couple of Read More...

  • Business Wire2 months ago

    NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit.

  • Business Wire2 months ago

    NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit.

  • Business Wire2 months ago

    NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit.

  • Business Wire2 months ago

    NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated (TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit.

  • InvestorPlace2 months ago

    5 Things to Know About Teleflex Stock

    Shares of Teleflex (NYSE:TFX) are flat so far in 2018 thanks to a quick decline in early August — one that interrupted Teleflex stock’s more or less steady upward movement, which investors had enjoyed since 2011. For those less familiar, Teleflex is a medical technology company with vascular, surgical and anesthesia products –v85% of which it sells directly to hospitals and healthcare providers, according to TFX’s 2017 annual report. Teleflex stock has regained a lot of what was loss already, but it’s still down slightly from 52-week highs.